Posts Tagged ‘Collaboration’
AXIM Rolls Medical Marijuana Ball in Ophthalmology
Medical marijuana has quickly gained acceptance as a viable treatment for a variety of health conditions, such as the side effects of chemotherapy, the neurodegenerative effects of Alzheimer’s disease, certain seizures and chronic pain without the addictive effects of opioids. But in ophthalmology, medical marijuana has encountered the headwinds of controversy. The American Glaucoma Society…
Read MoreAllergan Makes a Play in Gene Editing
With its licensing agreement to develop genome-editing programs with Editas Medicine to treat retinal diseases, Allergan has made a move to partner with one of the leading players in the CRISPR genome-editing space at a time when the field is poised to take off. That’s not Allergan’s hype. A recent report by San Francisco-based Grand…
Read MoreDeal between Minnesota Eye Consultants and Waud Capital Signals Change Coming to Ophthalmology
Two years ago, the principals at Minnesota Eye Consultants recognized the time had come to find a way to expand the practice. But doing so came with uncertainty. The group could opt to join a larger hospital-backed network. Or it could serve as the foundation for a practice roll-up, bringing other practices into the fold…
Read MoreJ&J/AMO Deal Remaking Landscape
The evolution of the ophthalmology sector continued with last week’s news that Johnson & Johnson would pay $4.3 billion to acquire Abbott Medical Optics, the company’s ophthalmology surgery business. The deal – if closed – promises to bring a newly engaged and energized Johnson & Johnson into ophthalmology. The company’s Vision Care business leads the…
Read MoreAlcon Looking at looking at EDOF and IOL Technology
Michael Onuscheck, global surgical franchise head for Alcon, a Novartis company, outlined the firm’s approach to innovation within the premium channel, which involves both internal development and external partnerships and acquisitions. In this decade, the focus of cataract innovation has shifted from safety, efficacy, and efficiency/throughput to refractive outcomes and meeting patients’ expectations with respect…
Read MoreBausch + Lomb Highlights Leadership in IOLs
Bausch + Lomb, a Valeant Pharmaceuticals company, remains the only firm with an FDA-approved accommodating IOL, the Crystalens AO. Andrew Chang, general manager and senior vice president of Bausch + Lomb US Surgical, highlighted clinical data from a study of long-term quality of vision and patient satisfaction with accommodating and multifocal IOLs conducted by John…
Read MoreEye on Five – April Edition
FDA Approves Avedro Corneal Collagen Cross-linking Platform The US Food and Drug Administration finally gave a green light to Avedro Inc. for its KXL System, a corneal collagen cross-linking platform for the treatment of progressive keratoconus. An FDA joint panel recommended approval in February last year, but a month later the agency denied approval, asking…
Read MoreEyeGate Finds New Paths to Dollars, Deal
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 072″] EyeGate Pharmaceuticals had hit a wall. Its venture investors were tapped out, and the company needed capital to continue running clinical trials on its lead product. CEO Stephen From turned to the public markets, leading the company through a unique – and small IPO. With $4 million from the offering,…
Read MorePrivate Funding Trends Presentation
Presenter: Jonathan Norris Jon Norris is a Managing Director with SVB Healthcare team, responsible for new business development. View Full Profile
Read MoreApplied Genetic Technologies Corporation (AGTC)
CEO Mark Shearman, MD, PhD, describes Applied Genetic Technologies Corp., known as AGTC, as a clinical-stage biotechnology company focused on developing its proprietary gene vector technology for treatment of orphan monogenic diseases of the retina. AGTC signed an R&D partnership with Biogen to oversee biological development and commercialization of its platform, which Dr. Shearman described…
Read MoreAlcon – Google Innovation: Visions of Ophthalmology in 2020
Participants: William J. Link, PhD Prior to Versant, Bill was a general partner at Brentwood Venture Capital. He founded, and served as chairman and CEO of Chiron Vision. Chiron Vision was sold to Bausch and Lomb in 1997. View Full Profile Laurent Attias Laurent Attias is currently Senior Vice President, Head of Strategy, BD&L and…
Read MoreGraybug
Graybug is developing injectable controlled-release technologies to allow dosing once every four to six months for the treatment of neovascular age-related macular degeneration (AMD), thereby reducing patient burden from 20+ injections yearly to two to three injections. The company is planning to file an Investigational New Drug application before year-end. Graybug licensed the simple, particle…
Read More